<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Transcatheter Cardiovascular Therapeutics</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Cutting balloons match lithotripsy for clearance of calcification </title>
      <description>
        <![CDATA[Results of the Shortcut study, presented last week at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco, indicated that cutting balloon angioplasty matched intravascular lithotripsy in coronary artery preparation of calcification for stent placement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725500</guid>
      <pubDate>Mon, 03 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725500-cutting-balloons-match-lithotripsy-for-clearance-of-calcification</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Pi-Cardia-Shortcut-11-3.webp?t=1762204994" type="image/jpeg" medium="image" fileSize="97330">
        <media:title type="plain">Pi-Cardia Shortcut device</media:title>
        <media:description type="plain">Pi-Cardia's Shortcut device is designed to split the leaflets of a pre-existing valve to enable safe transcatheter aortic valve replacement. Credit: Pi-Cardia Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Data suggest more than 10M people in the US have bad heart valves</title>
      <description>
        <![CDATA[The prevalence of valvular heart disease in the U.S. is tough to peg with any great precision, but an extrapolation of data from a new study would put the number at roughly 10.6 million people, a staggering number when the clinical and fiscal implications are considered.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725452</guid>
      <pubDate>Wed, 29 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725452-data-suggest-more-than-10m-people-in-the-us-have-bad-heart-valves</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardiovascular-heart-anatomy.webp?t=1745257885" type="image/jpeg" medium="image" fileSize="156646">
        <media:title type="plain">3D heart in chest</media:title>
      </media:content>
    </item>
    <item>
      <title>Data from Partner 3 low-risk affirms TAVR even with SAVR</title>
      <description>
        <![CDATA[Stakeholders of all stripes have wondered whether transcatheter aortic valve replacement devices could match their surgically implanted cousins for device durability, but seven-year data from the Partner 3 trial seems to suggest that patients, physicians, payers and regulators need not fret as the topline numbers showed no statistically significant difference for outcomes such as mortality and morbidity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725443</guid>
      <pubDate>Tue, 28 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725443-data-from-partner-3-low-risk-affirms-tavr-even-with-savr</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Sapien_M3-14apr25.webp?t=1766528025" type="image/jpeg" medium="image" fileSize="195288">
        <media:title type="plain">Edwards Lifesciences Sapien M3</media:title>
        <media:description type="plain">Edwards Lifesciences SAPIEN M3 Transcatheter Mitral Valve Replacement System. Credit: Edwards Lifesciences Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Will Medtronic’s RDN study drive Spyral-ing growth?</title>
      <description>
        <![CDATA[Medtronic plc’s SPYRAL HTN-ON MED trial demonstrated significantly greater reduction in blood pressure with the Symplicity Spyral renal denervation procedure at three years than a sham procedure in a study presented as featured clinical research at the 2025 Transcatheter Cardiovascular Therapeutics conference in San Francisco. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/725442</guid>
      <pubDate>Tue, 28 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725442-will-medtronics-rdn-study-drive-spyral-ing-growth</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/11-8-Medtronic---Symplicty-Spyral-HTN.webp?t=1667946402" type="image/png" medium="image" fileSize="281053">
        <media:title type="plain">Medtronic - Symplicty Spyral HTN</media:title>
        <media:description type="plain">The Symplicity Spyral RDN</media:description>
      </media:content>
    </item>
    <item>
      <title>Cordis rings up twin wins for Selution SLR at TCT</title>
      <description>
        <![CDATA[Cordis Corp. has quite a bit to crow about in this latter part of October 2025 with the unveiling of results of two studies that back the Miami Lakes, Fla.-based company’s Selution SLR drug-eluting balloon (DEB) for both de novo coronary artery stenosis and in-stent restenosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725441</guid>
      <pubDate>Tue, 28 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725441-cordis-rings-up-twin-wins-for-selution-slr-at-tct</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Picture-1-Selution-SLR-21aug23.webp?t=1761681889" type="image/jpeg" medium="image" fileSize="126580">
        <media:title type="plain">Selution SLR</media:title>
        <media:description type="plain">Cordis Corp. Selution SLR 018 drug-eluting balloon. Credit: Cordis Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Penumbra takes TCT by STORM</title>
      <description>
        <![CDATA[Penumbra Inc.’s 'resoundingly positive' results from its STORM-PE trial could see current guidelines for anticoagulant use in pulmonary embolism swept away in favor of mechanical thrombectomy. A deluge of favorable comments by experts and analysts followed the presentation during a late-breaking session at Transcatheter Cardiovascular Therapeutics, the annual scientific symposium of the Cardiovascular Research Foundation, which showed more than 50% improvement in treatment effect from Penumbra’s computer-assisted vacuum thrombectomy system plus anticoagulation compared to anticoagulation alone within two days with no increase in major adverse events. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/725421</guid>
      <pubDate>Mon, 27 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725421-penumbra-takes-tct-by-storm</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Penumbra_STORM_PE_RCT-27oct25.webp?t=1761601037" type="image/jpeg" medium="image" fileSize="182962">
        <media:title type="plain">Penumbra STORM PE</media:title>
      </media:content>
    </item>
    <item>
      <title>TCT presenter makes the case for addition by subtraction</title>
      <description>
        <![CDATA[Doctors and device makers are habituated to the notion that more devices equal better outcomes, but one presenter at this year’s Transcatheter Cardiovascular Therapeutics meeting in San Francisco argued that this is not always the case. James McCabe of Beth Israel Deaconess Medical Center in Boston said cardiologists may want to start thinking about whether a cardiology implant should stay implanted, a mindset that is anything but intuitively attractive to the modern practicing physician.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725420</guid>
      <pubDate>Mon, 27 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725420-tct-presenter-makes-the-case-for-addition-by-subtraction</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/TAVR.webp?t=1591138885" type="image/png" medium="image" fileSize="211348">
        <media:title type="plain">Illustration of TAVR device</media:title>
      </media:content>
    </item>
    <item>
      <title>One-year data for TRISCEND II favorable for quality of life</title>
      <description>
        <![CDATA[The first year of data from the TRISCEND II study of the Evoque tricuspid valve by Edwards Lifesciences Corp. confirm the notion that reduced regurgitation has a big impact on patient well-being. While one-year data support the device’s safety, cardiovascular mortality at one year does not seem to decisively favor the device over medical management.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713772</guid>
      <pubDate>Thu, 31 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713772-one-year-data-for-triscend-ii-favorable-for-quality-of-life</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/EVOQUE-02feb24.webp?t=1706907066" type="image/jpeg" medium="image" fileSize="57277">
        <media:title type="plain">Edwards EVOQUE</media:title>
        <media:description type="plain">The Evoque system is indicated for the improvement of health status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy.</media:description>
      </media:content>
    </item>
    <item>
      <title>ACURATE study leaves Boston Scientific with lots of homework</title>
      <description>
        <![CDATA[The ACURATE study of the Accurate neo2 TAVR device by Boston Scientific Corp., failed to demonstrate the device is non-inferior to established devices, but the COVID-19 pandemic threw up some roadblocks.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713773</guid>
      <pubDate>Thu, 31 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713773-acurate-study-leaves-boston-scientific-with-lots-of-homework</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/05-19-Boston-Scientific-Acurate-Neo2.webp?t=1621459216" type="image/png" medium="image" fileSize="319521">
        <media:title type="plain">Acurate Neo2 device image</media:title>
        <media:description type="plain">Acurate Neo2 aortic valve system. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sirolimus gaining ground on paclitaxel for peripheral artery use</title>
      <description>
        <![CDATA[The contest between the two main classes of antiproliferatives for circulatory system use continues as seen in a presentation at this year’s Transcatheter Cardiovascular Therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713752</guid>
      <pubDate>Wed, 30 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713752-sirolimus-gaining-ground-on-paclitaxel-for-peripheral-artery-use</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cardiovascular-stent-drug-eluting-device.webp?t=1623790472" type="image/png" medium="image" fileSize="1574468">
        <media:title type="plain">Illustration of stent angioplasty balloon in artery</media:title>
      </media:content>
    </item>
    <item>
      <title>ECLIPSE study suggests limited role for atherectomy in PCI cases</title>
      <description>
        <![CDATA[Atherectomy devices play a key role in dealing with calcified coronary arteries. But a study presented at this year’s Transcatheter Cardiovascular Therapeutics demonstrates that angioplasty balloons made a lot of headway in this clinical area, potentially pushing atherectomy devices into the fringes of routine practice.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713753</guid>
      <pubDate>Wed, 30 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713753-eclipse-study-suggests-limited-role-for-atherectomy-in-pci-cases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-with-blocked-arteries.webp?t=1678140599" type="image/png" medium="image" fileSize="369283">
        <media:title type="plain">Heart with blocked arteries</media:title>
      </media:content>
    </item>
    <item>
      <title>TAVR UNLOAD study fails to make case for earlier intervention</title>
      <description>
        <![CDATA[Some studies suggest a need for cardiologists to rethink their approach to device implant. However, the TAVR UNLOAD study failed to demonstrate a statistically significant difference between device implant and medical management for patients with aortic stenosis and low left ventricular ejection fraction.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713763</guid>
      <pubDate>Tue, 29 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713763-tavr-unload-study-fails-to-make-case-for-earlier-intervention</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/TAVR.webp?t=1591138885" type="image/png" medium="image" fileSize="211348">
        <media:title type="plain">Illustration of TAVR device</media:title>
      </media:content>
    </item>
    <item>
      <title>Edwards scores big at TCT with EARLY TAVR study</title>
      <description>
        <![CDATA[Transcatheter aortic valve replacement (TAVR) devices continue to make a splash in the world of medical technology, with the Sapien 3 by Edwards Lifesciences Corp. leading the way. Results of the EARLY TAVR study strongly suggest a need for implant in asymptomatic patients with severe aortic stenosis, a development that should help sustain and possibly increase sales of these devices for the next few years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713742</guid>
      <pubDate>Mon, 28 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713742-edwards-scores-big-at-tct-with-early-tavr-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/2-7-TAVR-edwards-sapien3.webp?t=1724185362" type="image/png" medium="image" fileSize="534933">
        <media:title type="plain">Device in heart</media:title>
        <media:description type="plain">The Edwards Sapien 3 TAVR. Credit: Edwards Lifesciences Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA’s Califf: Misinformation an emergency, docs must weigh in</title>
      <description>
        <![CDATA[FDA commissioner Bob Califf made it his mission to counter medical and food product misinformation, and described the dilemma as an emergency at an Oct. 28 public meeting.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713741</guid>
      <pubDate>Mon, 28 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713741-fdas-califf-misinformation-an-emergency-docs-must-weigh-in</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Robert-Califf.webp?t=1644961752" type="image/png" medium="image" fileSize="400884">
        <media:title type="plain">Robert Califf with American flag</media:title>
        <media:description type="plain">Robert Califf. Credit: U.S. FDA</media:description>
      </media:content>
    </item>
    <item>
      <title>Dueling trials highlight differences between Amulet and Watchman LAA closure devices</title>
      <description>
        <![CDATA[Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial appendage (LAA) to prevent ischemic stroke in patients with atrial fibrillation (Afib). In one of five presentations at the 34th Transcatheter Cardiovascular Therapeutics annual scientific symposium in Boston in mid-September, Abbott said device-related thrombosis or peri-device leak more frequently preceded strokes in patients with Watchman compared to those with Abbott’s Amplatzer Amulet device.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689971</guid>
      <pubDate>Mon, 26 Sep 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689971-dueling-trials-highlight-differences-between-amulet-and-watchman-laa-closure-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/09-26-Boston-Scientific-Watchman-FLX.webp?t=1774902951" type="image/png" medium="image" fileSize="547182">
        <media:title type="plain">Boston Scientific - Watchman FLX</media:title>
        <media:description type="plain">Watchman FLX. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Late-breaking trials at TCT provide good news for major med-tech device companies</title>
      <description>
        <![CDATA[The 2022 Transcatheter Cardiovascular Therapeutics annual meeting highlighted mostly positive outcomes from major trials conducted by nearly all the big players in the cardiac device market. Here’s our round-up of the meeting’s high points, with updates from Abbott Laboratories, Abiomed Inc., Boston Scientific Corp., Edwards Lifesciences Corp., Inari Medical Inc., Medtronic plc and Recor Medical Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689848</guid>
      <pubDate>Wed, 21 Sep 2022 01:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689848-late-breaking-trials-at-tct-provide-good-news-for-major-med-tech-device-companies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Cardiovascular-illustration.webp?t=1745257795" type="image/jpeg" medium="image" fileSize="245245">
        <media:title type="plain">Cardiovascular illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Encouraging outcomes for Medtronic’s Evolut as research shows challenges with SAVR after TAVR</title>
      <description>
        <![CDATA[Transcatheter aortic valve replacement (TAVR) continues to grow, so it is little surprise that the 2022 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting featured multiple presentations about TAVR-related devices and outcomes. The American College of Cardiology/American Heart Association’s latest guidelines recommends TAVR for patients over age 80 and surgery for those under age 65. Those in the middle can go either way, depending on comorbidities and patient preferences.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689844</guid>
      <pubDate>Wed, 21 Sep 2022 01:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689844-encouraging-outcomes-for-medtronics-evolut-as-research-shows-challenges-with-savr-after-tavr</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/08-25-Medtronic-Evolut-FX.webp?t=1629923807" type="image/png" medium="image" fileSize="217200">
        <media:title type="plain">Evolut FX image</media:title>
        <media:description type="plain">Evolut FX TAVR system. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Abiomed’s Impella devices show well in Japanese study of cardiogenic shock</title>
      <description>
        <![CDATA[Abiomed Inc., has worked the ventricular assist device (VAD) space for a number of years with its Impella series of VADs, and a study coming out of Japan seems to affirm investors’ confidence in these devices. This registry study demonstrated that the combination of Impella devices and extracorporeal membrane oxygenation (ECMO) provides a 30-day survival rate of more than three in four patients with cardiogenic shock, an outcome that is said to support the notion that the native heart tissue can recover from myocarditis, an especially salient consideration for those who contracted the SARS-CoV-2 virus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689793</guid>
      <pubDate>Tue, 20 Sep 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689793-abiomeds-impella-devices-show-well-in-japanese-study-of-cardiogenic-shock</link>
    </item>
    <item>
      <title>Medtronic and Recor show durable blood pressure reduction with renal denervation</title>
      <description>
        <![CDATA[In an unexpected turn of events, Medtronic plc presented results from the Symplicity HTN-3 trial at year 3 showed sustained reductions in blood pressure with radiofrequency renal denervation (RDN) for resistant hypertension, contrary to the trial’s results at the six-month mark—and it wasn’t alone in showing positive results for the procedure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689792</guid>
      <pubDate>Tue, 20 Sep 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689792-medtronic-and-recor-show-durable-blood-pressure-reduction-with-renal-denervation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/8-25-Medtronic-HQ.webp?t=1627334034" type="image/png" medium="image" fileSize="2189430">
        <media:title type="plain">Medtronic's headquarters in Minneapolis</media:title>
        <media:description type="plain">Operational headquarters. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Five years on, TAVR with self-expanding valve matches SAVR outcomes</title>
      <description>
        <![CDATA[It has long been known that patients recover more quickly from transcatheter aortic valve replacement (TAVR) than from open-heart surgery for valve replacement (SAVR) and results at two years looked good, too, with very similar outcomes. The question remained what happens in the longer term?]]>
      </description>
      <guid>http://www.bioworld.com/articles/513093</guid>
      <pubDate>Fri, 05 Nov 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/513093-five-years-on-tavr-with-self-expanding-valve-matches-savr-outcomes</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/TAVR.webp?t=1591138885" type="image/png" medium="image" fileSize="211348">
        <media:title type="plain">Illustration of TAVR device</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic study highlights patient hypertension treatment preferences at TCT 2021</title>
      <description>
        <![CDATA[A new study has found that despite the risk, many patients are open to interventional procedures such as renal denervation (RDN) if it can lead to improved blood pressure. RDN is performed under local anesthetic and uses radio frequency ablation to burn the nerves in the renal arteries. The process causes a reduction in nerve activity, which decreases blood pressure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513090</guid>
      <pubDate>Fri, 05 Nov 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/513090-medtronic-study-highlights-patient-hypertension-treatment-preferences-at-tct-2021</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-30-Medtronic-Symplicity-Spyral.webp?t=1585605773" type="image/png" medium="image" fileSize="358899">
        <media:title type="plain">3-30-Medtronic-Symplicity-Spyral.png</media:title>
        <media:description type="plain">Symplicity Spyral renal denervation system. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Stents, FFR software take a hit in study comparing PCI with coronary artery bypass</title>
      <description>
        <![CDATA[Despite the morbidity associated with coronary artery bypass graft, this procedure has never been entirely displaced by percutaneous coronary intervention. The results from the latest in a series of studies does not seem to help the case for drug-eluting stents (DES) for patients with three-vessel disease, as the data from this study failed to demonstrate non-inferiority for DES devices implanted with the help of fractional flow reserve measurement to ensure optimal stent placement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513044</guid>
      <pubDate>Thu, 04 Nov 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/513044-stents-ffr-software-take-a-hit-in-study-comparing-pci-with-coronary-artery-bypass</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-cross-section-valves.webp?t=1626905884" type="image/png" medium="image" fileSize="922624">
        <media:title type="plain">3D illustration of heart cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>Study finds Orchestra Biomed's Backbeat device reduces hypertension</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/430054</guid>
      <pubDate>Tue, 01 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430054-study-finds-orchestra-biomeds-backbeat-device-reduces-hypertension</link>
    </item>
    <item>
      <title>Intact's vascular scaffold hits endpoints in above-the-knee European study</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/430056</guid>
      <pubDate>Tue, 01 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430056-intacts-vascular-scaffold-hits-endpoints-in-above-the-knee-european-study</link>
    </item>
    <item>
      <title>Abbott unveils positive data on Mitraclip, Triclip</title>
      <description>
        <![CDATA[Abbott Laboratories had a busy Transcatheter Cardiovascular Therapeutics (TCT) 2019 conference. Among the news it generated was the unveiling of new analyses of the COAPT trial on the cost-effectiveness of Mitraclip vs. guideline-directed medical therapy (GDMT) alone in heart failure patients with secondary mitral regurgitation (MR).]]>
      </description>
      <guid>http://www.bioworld.com/articles/430053</guid>
      <pubDate>Tue, 01 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430053-abbott-unveils-positive-data-on-mitraclip-triclip</link>
    </item>
    <item>
      <title>Abbott's pivotal trial results for Portico boosted by new delivery system</title>
      <description>
        <![CDATA[SAN FRANCISCO – Abbott Laboratories expects that its self-expanding transcatheter aortic valve replacement (TAVR) system Portico will be able to become a top competitive product. A pivotal trial of Portico has found that the implant is noninferior to current FDA-approved TAVR systems that are marketed in the U.S. The results from the 750-patient, randomized trial were presented here last week at the Transcatheter Cardiovascular Therapeutics (TCT) conference.]]>
      </description>
      <guid>http://www.bioworld.com/articles/429991</guid>
      <pubDate>Mon, 30 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/429991-abbotts-pivotal-trial-results-for-portico-boosted-by-new-delivery-system</link>
    </item>
    <item>
      <title>Investigator-led study finds BSX's Acurate Neo not noninferior vs. Edwards' Sapien 3</title>
      <description>
        <![CDATA[SAN FRANCISCO – As the transcatheter aortic valve replacement (TAVR) field matures, it is becoming increasingly difficult to develop a new implant that can distinguish itself vs. competitors. The incremental benefits are narrowing rapidly, making it tough to distinguish new iterations from one another using standard, randomized trials.]]>
      </description>
      <guid>http://www.bioworld.com/articles/429990</guid>
      <pubDate>Mon, 30 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/429990-investigator-led-study-finds-bsxs-acurate-neo-not-noninferior-vs-edwards-sapien-3</link>
    </item>
    <item>
      <title>Shockwave reports positive registry data on pre-stent calcium fracture via IVL</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/430214</guid>
      <pubDate>Fri, 27 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430214-shockwave-reports-positive-registry-data-on-pre-stent-calcium-fracture-via-ivl</link>
    </item>
    <item>
      <title>Pascal holds own in one-year CLASP data, as speculation abounds on Mitraclip comparisons</title>
      <description>
        <![CDATA[SAN FRANCISCO – Mitraclip from Abbott Park, Ill.-based Abbott Laboratories, has long been the only minimally invasive mitral valve repair device that's approved by the FDA. Edwards Lifesciences Corp., of Irvine, Calif., aims to challenge that dominance with its Pascal. This week at the Transcatheter Cardiovascular Therapeutics (TCT) conference, positive one-year data from the small CLASP study on Pascal were presented, offering a further glimpse of data for comparison.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430212</guid>
      <pubDate>Fri, 27 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430212-pascal-holds-own-in-one-year-clasp-data-as-speculation-abounds-on-mitraclip-comparisons</link>
    </item>
    <item>
      <title>Data, analytics and Dx crucial as medical device industry transforms into med tech</title>
      <description>
        <![CDATA[SAN FRANCISCO – The accelerating confluence of information technology and medical devices is transforming the latter into a true embodiment of med tech. That was the conclusion of early keynote sessions at the Transcatheter Cardiovascular Therapeutics (TCT) that began here yesterday.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430116</guid>
      <pubDate>Thu, 26 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430116-data-analytics-and-dx-crucial-as-medical-device-industry-transforms-into-med-tech</link>
    </item>
  </channel>
</rss>
